XYNOMIC PHARMACEUTICALS HOLDINGS, INC.
XYNOMIC PHARMACEUTICALS HOLDINGS, INC. (BCACU): 3 pipeline candidates. Updated within the last hour.
BioSniper Score
3-factor signal · derived from public data
N/A
D/E -1.04 · 0% dilution
Lead: Phase 1/Phase 2
3 candidates
N/A
N/A
A transparent, data-derived signal for XYNOMIC PHARMACEUTICALS HOLDINGS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$93K
Quarterly Burn
—
Runway
—
Revenue
—
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| abexinostat | Phase 1/Phase 2 |
| xp-102 | Preclinical |
| xp-105 | Preclinical |
Frequently asked questions
How many drug candidates are in XYNOMIC PHARMACEUTICALS HOLDINGS, INC.'s pipeline?
XYNOMIC PHARMACEUTICALS HOLDINGS, INC. (BCACU) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is XYNOMIC PHARMACEUTICALS HOLDINGS, INC.'s lead drug candidate?
XYNOMIC PHARMACEUTICALS HOLDINGS, INC.'s most advanced tracked candidate is abexinostat (Phase 1/Phase 2) for Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL) or Relapsed/Refractory Diffuse Large B-cell Lymphoma (r/r DLBCL).
Who is the CEO of XYNOMIC PHARMACEUTICALS HOLDINGS, INC.?
Yinglin Mark Xu is the chief executive officer of XYNOMIC PHARMACEUTICALS HOLDINGS, INC. (BCACU).
Get the full picture on XYNOMIC PHARMACEUTICALS HOLDINGS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.